Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ovalbumin-containing core-shell implants suitable to obtain a delayed IgG1 antibody response in support of a biphasic pulsatile release profile in mice.
Amssoms K, Born PA, Beugeling M, De Clerck B, Van Gulck E, Hinrichs WLJ, Frijlink HW, Grasmeijer N, Kraus G, Sutmuller R, Simmen K, Baert L. Amssoms K, et al. Among authors: sutmuller r. PLoS One. 2018 Aug 30;13(8):e0202961. doi: 10.1371/journal.pone.0202961. eCollection 2018. PLoS One. 2018. PMID: 30161264 Free PMC article.
Humanized mice recapitulate key features of HIV-1 infection: a novel concept using long-acting anti-retroviral drugs for treating HIV-1.
Nischang M, Sutmuller R, Gers-Huber G, Audigé A, Li D, Rochat MA, Baenziger S, Hofer U, Schlaepfer E, Regenass S, Amssoms K, Stoops B, Van Cauwenberge A, Boden D, Kraus G, Speck RF. Nischang M, et al. Among authors: sutmuller r. PLoS One. 2012;7(6):e38853. doi: 10.1371/journal.pone.0038853. Epub 2012 Jun 13. PLoS One. 2012. PMID: 22719966 Free PMC article.
CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity.
Solomon I, Amann M, Goubier A, Arce Vargas F, Zervas D, Qing C, Henry JY, Ghorani E, Akarca AU, Marafioti T, Śledzińska A, Werner Sunderland M, Franz Demane D, Clancy JR, Georgiou A, Salimu J, Merchiers P, Brown MA, Flury R, Eckmann J, Murgia C, Sam J, Jacobsen B, Marrer-Berger E, Boetsch C, Belli S, Leibrock L, Benz J, Koll H, Sutmuller R, Peggs KS, Quezada SA. Solomon I, et al. Among authors: sutmuller r. Nat Cancer. 2020 Dec;1(12):1153-1166. doi: 10.1038/s43018-020-00133-0. Epub 2020 Nov 9. Nat Cancer. 2020. PMID: 33644766 Free PMC article.
Adoptive T cell immunotherapy of human uveal melanoma targeting gp100.
Sutmuller RP, Schurmans LR, van Duivenvoorde LM, Tine JA, van Der Voort EI, Toes RE, Melief CJ, Jager MJ, Offringa R. Sutmuller RP, et al. J Immunol. 2000 Dec 15;165(12):7308-15. doi: 10.4049/jimmunol.165.12.7308. J Immunol. 2000. PMID: 11120866
Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses.
Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, Toes RE, Offringa R, Melief CJ. Sutmuller RP, et al. J Exp Med. 2001 Sep 17;194(6):823-32. doi: 10.1084/jem.194.6.823. J Exp Med. 2001. PMID: 11560997 Free PMC article.
Antitumor efficacy of wild-type p53-specific CD4(+) T-helper cells.
Zwaveling S, Vierboom MP, Ferreira Mota SC, Hendriks JA, Ooms ME, Sutmuller RP, Franken KL, Nijman HW, Ossendorp F, Van Der Burg SH, Offringa R, Melief CJ. Zwaveling S, et al. Among authors: sutmuller rp. Cancer Res. 2002 Nov 1;62(21):6187-93. Cancer Res. 2002. PMID: 12414646
Rejection of intraocular tumors by CD4(+) T cells without induction of phthisis.
Schurmans LR, Diehl L, den Boer AT, Sutmuller RP, Boonman ZF, Medema JP, van der Voort EI, Laman J, Melief CJ, Jager MJ, Toes RE. Schurmans LR, et al. Among authors: sutmuller rp. J Immunol. 2001 Nov 15;167(10):5832-7. doi: 10.4049/jimmunol.167.10.5832. J Immunol. 2001. PMID: 11698457
30 results